The value of cell block based on fine needle aspiration for lung cancer diagnosis

Dong, Zhengwei; Li, Hui; Zhou, Jun; Zhang, Wei; Wu, Chunyan

doi:10.21037/jtd.2017.07.91

Cited by 21 publications

(27 citation statements)

References 23 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of these antibodies with formol fixed cytological material requires validation steps and comparative approaches with results obtained with tissue biopsies performed preferably on the same patient. In general, the cytological samples examined after formol fixation and inclusion into paraffin blocks (cytoblocks) give similar results to those obtained with tissue samples [ 24 , 25 , 26 , 27 ]. The other cytological approaches (absence of fixation, fixation other than with formol, cytological smears, cytology after centrifugation onto slides) make standardization of ICC approaches difficult.…”

Section: The Therapeutic Targets Identified By Immunohistochemistrsupporting

confidence: 61%

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

Hofman

Lassalle

Bence

et al. 2018

Cancers

View full text Add to dashboard Cite

The identification of certain genomic alterations (EGFR, ALK, ROS1, BRAF) or immunological markers (PD-L1) in tissues or cells has led to targeted treatment for patients presenting with late stage or metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or by molecular biology (MB) techniques. These approaches are often complementary but depending on, the quantity and quality of the biological material, the urgency to get the results, the access to technological platforms, the financial resources and the expertise of the team, the choice of the approach can be questioned. The possibility of detecting simultaneously several molecular targets, and of analyzing the degree of tumor mutation burden and of the micro-satellite instability, as well as the recent requirement to quantify the expression of PD-L1 in tumor cells, has led to case by case development of algorithms and international recommendations, which depend on the quality and quantity of biological samples. This review will highlight the different predictive biomarkers detected by IHC for treatment of lung cancer as well as the present advantages and limitations of this approach. A number of perspectives will be considered.

show abstract

Section: The Therapeutic Targets Identified By Immunohistochemistrsupporting

confidence: 61%

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

Hofman

Lassalle

Bence

et al. 2018

Cancers

View full text Add to dashboard Cite

show abstract

“…Similar study was conducted by Dong Z and Busra Al-Ayadhy with use of limited IHC panel in cell block section, where they could further sub-classify all the entities. 15,16 The most frequent malignant entity in our study was SCC constituting 42%, followed by adenocarcinoma. Singh R conducted similar studies on FNAC of lung mass and found adenocarcinoma as the most common malignant entity.…”

Section: Discussionmentioning

confidence: 63%

Role of immunohistochemistry in cell block sections for categorization of non-small cell carcinoma of lung

Yasmin¹,

Haque²,

Islam³

et al. 2019

Birdem Med J

View full text Add to dashboard Cite

Background: Computed tomography (CT) guided fine needle aspiration and cytology (FNAC) is a useful modality which aids in early and fairly accurate diagnosis of mass lesions of lungs specially the malignant ones. Previously in patients with primary lung cancer the most important consideration was to discriminate between small cell and non-small cell carcinoma (NSCC) of the lung. With advancement of cancer therapy, sub-typing of NSCC has become very important. The aims of the study were to evaluate the pathological spectrum of the pulmonary diseases in CT guided FNAC of lung mass lesions and utility of limited immunohistochemistry (IHC) in cell block sections to subcategorize NSCC. Methods: The study was carried out at Department of Histopathology in Armed Forces Institute of Pathology from 1st January 2018 to 31st December 2018. It involved total 140 patients who underwent CT guided FNAC in Combined Military Hospital, Dhaka for lung mass lesions. Aspiration was done by pathologist and obtained material was used to make slide smears and cell blocks. Both FNAC smears and cell block sections were examined by histopathologists. The entities diagnosed as NSCC and poorly differentiated carcinomas in FNAC were treated with limited IHC panel in cell block sections. Results: Out of 140 cases 110 were male and 30 were female patients. Age range was from 18 to 85 years, (mean age 60±13.5). Total 83(59%) malignant neoplasms and 57(41%) benign lesions were diagnosed. Among the benign lesions, 28 were diagnosed as granulomatous lesion suggestive of tuberculosis and rests were nonspecific inflammatory lesion. In FNAC smear, small cell carcinoma was diagnosed in 16.9% (14/83) of all malignant lesions, squamous cell carcinoma (SCC) in 26.5% (22/83) patients and adenocarcinoma in 22.9% (19/83) patients. Twenty-five patients were categorized as NSCC as they could not be further subcategorized in FNAC as SCC/adenocarcinoma. Three patients were categorized as poorly differentiated carcinoma as their cytological features could not rule in/out small cell carcinoma. NSCC and poorly differentiated carcinoma diagnosed by FNAC were33.7% (28/83). Cell blocks of all of them were examined, three of NSCC cell blocks were found inadequate for evaluation. All of the rest cases underwent limited IHC panel in cell block sections and were further subcategorized; 13 as SCC and 12 as adenocarcinoma. Total cases of SCC diagnosed in the study after IHC on cell block sections were 35/83(42%) followed by adenocarcinoma 31/83, (33.35%). Conclusion: CT guided FNAC is an effective tool and can be used for fairly accurate and early diagnosis of lung mass lesions. Immunohistochemistry on cell block sections can be used as an effective tool for categorization of NSCC. Birdem Med J 2019; 9(3): 223-228

show abstract

“…The procedure for cytological cell block processing was similar as described previously [11,12]. Simply, samples were placed into ThinPrep (HOLOGIC Gen-Probe, San Diego, CA, USA) cytology test (TCT) preservation solution.…”

Section: Cytology Sample Processing and Tumor Cell Countingmentioning

confidence: 99%

Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer

Dong

Liu²,

Jiang³

et al. 2020

J. Cancer

Self Cite

View full text Add to dashboard Cite

Introduction: Programmed death-ligand 1 (PD-L1) staining is used in clinical practice to guide the proper use of immune checkpoint inhibitors. This study aimed to investigate the accuracy of PD-L1 staining of non-small cell lung cancer (NSCLC) cytological cell block samples. Methods: Paired cytological cell block and surgical resection samples were consecutively collected from January 2016 to February 2017 in Shanghai Pulmonary Hospital, Tongji University. Two trial-validated PD-L1 assays (28-8 and SP142) were used to quantify PD-L1 expression. Results: A total of 112 pairs of specimens were collected, including 68(60.7%) adenocarcinomas and 28(25.0%) squamous cell carcinomas. Based on a tumor proportion score (TPS) cutoff of 1% for the 28-8 and SP142 assays, PD-L1 expression was positive in 78.6% and 58.9% of surgical samples respectively, while PD-L1 expression was positive in 67.9% and 25.0% of cytological cell block samples. Based on staining by each antibody, fair to substantial concordance of PD-L1 expression was observed for cytological cell block specimens as compared to surgical resection ( ranges from 0.377 to 0.686). However, as the tumor cells in the cell block specimen increased, the consistency of PD-L1 expression increased. The concordance of PD-L1 expression in cell blocks with abundant cellularity was nearly perfect with various cutoffs (28-8: tumor cells over 400; SP142: tumor cells over 500). Conclusion: Cytological cell block specimens may serve as a surrogate for PD-L1 staining in patients of NSCLC when more than 400-500 cancer cells were contained (over 400 cancer cells for 28-8, over 500 cancer cells for SP142).

show abstract

The value of cell block based on fine needle aspiration for lung cancer diagnosis

Cited by 21 publications

References 23 publications

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

Role of immunohistochemistry in cell block sections for categorization of non-small cell carcinoma of lung

Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About